Actinium Pharmaceuticals (ATNM) CEO On New Radiotherapy Candidate For Cancer Patients

Actinium Pharmaceuticals (ATNM) is a clinical-stage biopharmaceutical company. CEO Sandesh Seth discusses ATNM which is developing a new radiotherapy candidate for cancer patients. The company released promising results from trials of its radiotherapy candidate IOMAB-B which could help patients with relapsed or refractory acute myeloid leukemia receive bone marrow transplants. He then goes over the outlook for the company. Tune in to find out more about the stock market today.

Morning Trade Live

14 Nov 2022

SHARE

ON AIR
4:00 am
Fast Market
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Trading 360
REPLAY
ON AIR
4:00 am
Fast Market
REPLAY
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
education
9:30 am
Your First Trade
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
1:30 pm
Trading 360
REPLAY
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
education
4:30 pm
Your First Trade
REPLAY
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
education
8:00 pm
Your First Trade
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now